This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Myopic choroidal neovascularisation

Myopic choroidal neovascularisation
Reviewed by Jonathan Chan

1 August 2015 | Jonathan Chan | EYE - Vitreo-Retinal

This is a review article summarising the latest myopic CNV (choroidal neovascularisation) literature in the clinical experience and management outcomes for recommendation algorithm. The aetiology of the myopic CNV was discussed by the authors under the heading of the heredo-degenerative and haemodynamic theories for the development of myopic CNV. The diagnosis of myopic CNV was based on the clinical examination, including fundal biomicroscopy, fluorescein angiogram and optical coherence tomography (OCT). The majority of the myopic CNV presents as a classic pattern on the fluorescein angiogram. On OCT imaging the majority represents a highly refractive area above the retinal pigment epithelium – type 2 CNV with minimal subretinal fluid. Fundus autofluoresence showed the increase in the accumulative lipofuscin within the retinal pigment epithelium. Lucentis (ranibizumab) is the only licensed anti-VEGF therapy for treatment of myopic CNV. Avastin (bevacizumab) is not approved for intraocular use and evidence on its safety and efficacy profile is limited. Aflibercept (Eylea) for myopic CNV is undergoing phase III, multicentre, randomised trial at present. Recent reports on Eylea indicate sustained best corrected visual acuity gains of up to 12 months. The authors recommend a treatment algorithm for myopic CNV. After initial assessment prompt treatment with a single intravitreal injection of anti-VEGF therapy is recommended due to the superior efficacy of anti-VEGFs over other treatment modalities. After the initial injection, the patients will be monitored monthly for months one and two and then at least three-monthly in the first year. If patients have positive activity or visual loss then they will have a repeat injection. After one year, the monitoring frequency should be established by the retinal specialist in consultation with the patient and the patient should be advised to return if they experience any drop in vision. 

Myopic choroidal neovascularisation: current concepts and update on clinical management.
Wong TY, Ohno-Matsui K, Leveziel N, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2015;99:289-96.
Share This
CONTRIBUTOR
Jonathan Chan

Royal Hallamshire Hospital, Sheffield, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency